Form 8-K - Current report:
SEC Accession No. 0001437749-24-024718
Filing Date
2024-08-06
Accepted
2024-08-06 07:08:39
Documents
15
Period of Report
2024-08-02
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 1.02: Termination of a Material Definitive Agreement
Item 2.02: Results of Operations and Financial Condition
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tgtx20240805_8k.htm   iXBRL 8-K 41897
2 EXHIBIT 99.1 ex_708490.htm EX-99.1 160696
  Complete submission text file 0001437749-24-024718.txt   357348

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA tgtx-20240802.xsd EX-101.SCH 3408
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE tgtx-20240802_def.xml EX-101.DEF 11423
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE tgtx-20240802_lab.xml EX-101.LAB 15309
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tgtx-20240802_pre.xml EX-101.PRE 11583
17 EXTRACTED XBRL INSTANCE DOCUMENT tgtx20240805_8k_htm.xml XML 2842
Mailing Address 2 GANSEVOORT STREET, 9TH FLOOR NEW YORK NY 10014
Business Address 2 GANSEVOORT STREET, 9TH FLOOR NEW YORK NY 10014 (212) 554-4484
TG THERAPEUTICS, INC. (Filer) CIK: 0001001316 (see all company filings)

EIN.: 363898269 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-32639 | Film No.: 241177060
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)